marek health tirzepatide Working with has been nothing short of life changing for me.“ Guided Optimization & Premier Telehealth

Introduction Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are key therapies for type 2 diabetes and obesity, regulating blood glucose by mimicking endogenous GLP-1

Learn more about vaginal dryness, including the symptoms, causes and treatments.

The rapidly evolving landscape for CKD-protective therapies in type 2 diabetes currently includes sodium-glucose cotransporter 2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1 RA), both of which demonstrate cardiorenal outcome benefits

Mechanism Target

First discovered by Lee and colleagues in 2015, this peptide has a primary structure of Met-Arg-Trp-Gln-Glu-Met-Gly-Tyr-Ile-Phe-Tyr-Pro-Arg-Lys-Leu-Arg, with the first 11 amino acid residues being highly conserved across 14 species, indicating its evolutionary importance[1][3]

New research suggests GLP-1 drugs may lower the risk of certain cancers, but could also raise the likelihood of developing kidney cancer.